Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Florian Moik, Jakob M. Riedl, Cihan Ay
Topics & Concepts
MedicineOsimertinibChemotherapyOncologyInternal medicineLung cancerEpidermal growth factor receptorAdenocarcinomaCancerErlotinibLung Cancer Treatments and MutationsVenous Thromboembolism Diagnosis and ManagementColorectal Cancer Treatments and Studies